Despite advancements in targeted therapies—such as FLT3, IDH, and BCL-2 inhibitors—treatment resistance and relapse rates remain high, and the 5-year survival rate for AML patients remains disappointingly low (Zhang B. et al., 2021; Forsberg and Konopleva, 2024; Mohamed Jiffry et al., 2023). This evidence concerns the gene IDH1 and acute myeloid leukemia.